Improve Your Commercial Growth Strategy with Custom-Tailored Intelligence

LEARN MORE

NanoString Inks $45 million CDx Collaboration With Celgene

by

NanoString will utilize IP from a 20-gene expression assay developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMP) to develop a companion diagnostic test to support clinical validation of Celgene’s REVLIMID®. NanoString could receive up to $45 million in payments under the deal.

Company press release

PageLines